A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database

Abstract

Background:

Limited information is available on associations between COVID-19 vaccines and central nervous system (CNS) demyelinating diseases.

Objectives:

We investigated potential safety signals for CNS demyelinating diseases related to COVID-19 vaccines using the World Health Organization pharmacovigilance database.

Methods:

Disproportionality analyses of CNS demyelinating disease following COVID-19 vaccination were performed by calculating the information component (IC) or the reporting odds ratio (ROR) compared with those for the entire database and for all other viral vaccines.

Results:

We identified 715 cases of optic neuritis, 515 of myelitis, 220 of acute disseminated encephalomyelitis (ADEM), and 2840 total CNS demyelinating events adverse drug reactions from July 2020 through February 2022. For mRNA-based and ChAdOx1 nCoV-19 vaccines, there were no potential safety signals of disproportionality for optic neuritis (IC₀₂₅ = −0.93, ROR₀₂₅ = 0.38; IC₀₂₅ = −1.76, ROR₀₂₅ = 0.26), myelitis (IC₀₂₅ = −0.69, ROR₀₂₅ = 0.50; IC₀₂₅ = −0.63, ROR₀₂₅ = 0.53), ADEM (IC₀₂₅ = −1.05, ROR₀₂₅ = 0.33; IC₀₂₅ = −1.76, ROR₀₂₅ = 0.20), or overall CNS demyelinating disease events (IC₀₂₅ = −0.66, ROR₀₂₅ = 0.52; IC₀₂₅ = −1.31, ROR₀₂₅ = 0.34) compared with other viral vaccines.

Conclusion:

As with other viral vaccines, our disproportionality analyses indicate that the risk of COVID-19 vaccine-associated CNS demyelinating disease was low.

Keywords

COVID-19 vaccination myelitis acute disseminated encephalomyelitis multiple sclerosis optic neuritis

Get full access to this article

View all access options for this article.

References

Callaway

Ledford

. How bad is Omicron? What scientists know so far. Nature 2021; 600(7888): 197–199.

Omer

Yildirim

Forman

. Herd immunity and implications for SARS-CoV-2 control. JAMA 2020; 324: 2095–2096.

Pascual-Iglesias

Canton

Ortega-Prieto

, et al. An overview of vaccines against SARS-CoV-2 in the COVID-19 pandemic era. Pathogens 2021; 10: 1030.

Karussis

Petrou

. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 2014; 13(3): 215–224.

Salemi

D’Amelio

. Could autoimmunity be induced by vaccination? Int Rev Immunol 2010; 29: 247–269.

Mailand

Frederiksen

. Vaccines and multiple sclerosis: A systematic review. J Neurol 2017; 264: 1035–1050.

van der Laan

Gould

Tanir

, et al. Safety of vaccine adjuvants: Focus on autoimmunity. Vaccine 2015; 33: 1507–1514.

Rinaldi

Bellucci

Romano

, et al. ADEM after ChAdOx1 nCoV-19 vaccine: A case report. Mult Scler 2022; 28: 1151–1154.

Garg

Paliwal

. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci 2022; 43(1): 3–40.

10.

Ismail

Salama

. A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol 2022; 362: 577765.

11.

Voysey

Clemens

SAC

Madhi

, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99–111.

12.

Roman

Gracia

Torres

, et al. Acute transverse myelitis (ATM): Clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Front Immunol 2021; 12: 653786.

13.

Frontera

Tamborska

Doheim

, et al. Neurological events reported after COVID-19 vaccines: An analysis of VAERS. Ann Neurol 2022; 91: 756–771.

14.

Lindquist

. VigiBase, the WHO Global ICSR database system: Basic facts. Drug Inf J 2008; 42: 409–419.

15.

Brown

Wood

. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20: 109–117.

16.

Thompson

Banwell

Barkhof

, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17: 162–173.

17.

Schwenkenbecher

Wurster

Suhs

, et al. Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurol 2018; 17: 498.

18.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Maintenance of the ICH guideline on clinical safety data management: Data elements for transmission of individual case safety reports E2B(R2), https://admin.ich.org/sites/default/files/inline-files/E2B_R2_Guideline.pdf (2001, accessed 9 March 2021).

19.

Bate

Lindquist

Edwards

, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54(4): 315–321.

20.

Salem

Manouchehri

Moey

, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol 2018; 19(12): 1579–1589.

21.

Noren

Hopstadius

Bate

. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 2013; 22(1): 57–69.

22.

Park

Kim

Song

. A disproportionality analysis for association of systemic capillary leak syndrome with COVID-19 vaccination using the World Health Organization pharmacovigilance database. Vaccines 2022; 10: 835–842.

23.

Park

Kim

, et al. Association of cerebral venous thrombosis with mRNA COVID-19 vaccines: A disproportionality analysis of the World Health Organization pharmacovigilance database. Vaccines 2022; 10: 799–808.

24.

Rothman

Lanes

Sacks

. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004; 13(8): 519–523.

25.

De Bruin

Pettersson

Meyboom

, et al. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 2005; 26(6): 590–597.

26.

European Medicine Agency. COVID—19 vaccine safety update—Comirnaty, COVID-19 vaccine Janssen, Nuvaxovid, Spikevax, Vaxzevria, www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-20-january-2022_en.pdf (2022, accessed 12 March 2022)

27.

von Csefalvay

. VAERS data reveals no increased risk of neuroautoimmune adverse events from COVID-19 vaccines. medRxiv, 2021, https://www.medrxiv.org/content/10.1101/2021.06.13.21258851v2

28.

Achiron

Dolev

Menascu

, et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. Mult Scler 2021; 27(6): 864–870.

29.

Mealy

Cook

Pache

, et al. Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2018; 23: 78–82.

30.

Lotan

Romanow

Levy

. Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases. Mult Scler Relat Disord 2021; 55: 103189.

31.

Dinoto

Sechi

Ferrari

, et al. Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD. Mult Scler Relat Disord 2022; 58: 103424.

32.

Agmon-Levin

Kivity

Szyper-Kravitz

, et al. Transverse myelitis and vaccines: A multi-analysis. Lupus 2009; 18(13): 1198–1204.

33.

Velikova

Georgiev

. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int 2021; 41(3): 509–518.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

0.89 MB

0.87 MB